INVESTORS

SOLID SCIENCE - NEAR TERM  
GROWTH OPPORTUNITY

Gene therapy is one of the hottest growth areas in biotech with about  $10 Billion invested annually  over the last several years.

Cellastra is targeting dermal scarring, a market expected to reach  46 B USD by 2028.

CELLEXA Gene Therapy applied in the wound area switches on the pproduction of natural anti-scarring peptides already found to be safe and effective in clinical studies to date.

Rather than trying to apply topical treatment for weeks or months,one treatment with CELLEXA  turns on the cell factory in local cell of he targeted wound area to produce anti-scarring peptides for many weeks or months

See Investor Contacts:

Investor.jpg

Welcome to

THE NEXT BIG THING

Cellastra Presentation
31 March, 2022


 

Cellastra Execcutive Summary

31 March, 2022

 

 

December 10, 2021